INTRODUCTION: The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial. METHODS: The study population consisted of 54 inoperable patients with MPM enrolled between 2003 and 2006. ERCC1 expression was evaluated by immunohistochemistry (IHC) on the formalin-fixed paraffin-embedded diagnostic biopsies. The immunoreaction was quantified using an H-score (staining intensity multiplied by a proportion score based on the percentage of stained tumor cells). The cutoff point was chosen as the median H-score in a cohort of non-neoplastic pleural samples from patients with benign thoracic diseases. The tumor samples were separated according to this cutoff point into ERCC1-negative (H-score ≤ median) and ERCC1-positive (H-score > median) cases. RESULTS: Fifty patients had tumor tissue available for IHC. There were 20 ERCC1-positive and 30 ERCC1-negative tumors. There was a significant correlation between negative ERCC1 status and long progression-free survival (PFS). Median PFS was 10.9 months in the ERCC1-negative group, opposed to 6.7 months in the ERCC1-positive group (p = 0.053). Multivariate Cox regression showed ERCC1 to be the only variable significantly associated with PFS, and ERCC1-positive patients had a significantly shorter time to progression compared with ERCC1-negative patients (hazard ratios, 2.24; 95% confidence interval, 1.16-4.34; p = 0.0163). We found no association between ERCC1 status and overall survival. CONCLUSION: Our retrospective study in MPM patients treated with cisplatin/vinorelbine suggests that low ERCC1 expression, evaluated by IHC, may predict longer PFS, a result that warrants further validation.
INTRODUCTION: The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial. METHODS: The study population consisted of 54 inoperable patients with MPM enrolled between 2003 and 2006. ERCC1 expression was evaluated by immunohistochemistry (IHC) on the formalin-fixed paraffin-embedded diagnostic biopsies. The immunoreaction was quantified using an H-score (staining intensity multiplied by a proportion score based on the percentage of stained tumor cells). The cutoff point was chosen as the median H-score in a cohort of non-neoplastic pleural samples from patients with benign thoracic diseases. The tumor samples were separated according to this cutoff point into ERCC1-negative (H-score ≤ median) and ERCC1-positive (H-score > median) cases. RESULTS: Fifty patients had tumor tissue available for IHC. There were 20 ERCC1-positive and 30 ERCC1-negative tumors. There was a significant correlation between negative ERCC1 status and long progression-free survival (PFS). Median PFS was 10.9 months in the ERCC1-negative group, opposed to 6.7 months in the ERCC1-positive group (p = 0.053). Multivariate Cox regression showed ERCC1 to be the only variable significantly associated with PFS, and ERCC1-positive patients had a significantly shorter time to progression compared with ERCC1-negative patients (hazard ratios, 2.24; 95% confidence interval, 1.16-4.34; p = 0.0163). We found no association between ERCC1 status and overall survival. CONCLUSION: Our retrospective study in MPM patients treated with cisplatin/vinorelbine suggests that low ERCC1 expression, evaluated by IHC, may predict longer PFS, a result that warrants further validation.
Authors: Daniel C Christoph; Bernadette Reyna Asuncion; Celine Mascaux; Cindy Tran; Xian Lu; Murry W Wynes; Thomas C Gauler; Jeremias Wohlschlaeger; Dirk Theegarten; Volker Neumann; Rodrigo Hepp; Stefan Welter; Georgios Stamatis; Andrea Tannapfel; Martin Schuler; Wilfried E Eberhardt; Fred R Hirsch Journal: J Thorac Oncol Date: 2012-09 Impact factor: 15.609
Authors: Fabian Dominik Mairinger; Robert Werner; Elena Flom; Jan Schmeller; Sabrina Borchert; Michael Wessolly; Jeremias Wohlschlaeger; Thomas Hager; Thomas Mairinger; Jens Kollmeier; Daniel Christian Christoph; Kurt Werner Schmid; Robert Fred Henry Walter Journal: Virchows Arch Date: 2017-05-02 Impact factor: 4.064
Authors: Adam Szulkin; Rita Otvös; Carl-Olof Hillerdal; Aytekin Celep; Eviane Yousef-Fadhel; Henriette Skribek; Anders Hjerpe; László Székely; Katalin Dobra Journal: BMC Cancer Date: 2014-09-24 Impact factor: 4.430
Authors: Martin Lehnert; Daniel G Weber; Dirk Taeger; Irina Raiko; Jens Kollmeier; Susann Stephan-Falkenau; Thomas Brüning; Georg Johnen Journal: BMC Res Notes Date: 2020-07-29
Authors: Sabrina Borchert; Pia-Maria Suckrau; Michael Wessolly; Elena Mairinger; Balazs Hegedus; Thomas Hager; Thomas Herold; Wildfried E E Eberhardt; Jeremias Wohlschlaeger; Clemens Aigner; Agnes Bankfalvi; Kurt Werner Schmid; Robert F H Walter; Fabian D Mairinger Journal: J Oncol Date: 2019-12-23 Impact factor: 4.375
Authors: Robert Fred Henry Walter; Claudia Vollbrecht; Robert Werner; Thomas Mairinger; Jan Schmeller; Elena Flom; Jeremias Wohlschlaeger; Nikolaos Barbetakis; Dimitrios Paliouras; Fotios Chatzinikolaou; Vasilis Adamidis; Kosmas Tsakiridis; Paul Zarogoulidis; Georgia Trakada; Daniel Christian Christoph; Kurt Werner Schmid; Fabian Dominik Mairinger Journal: J Cancer Date: 2016-09-13 Impact factor: 4.207